Osteonecrosis of the jaw associated with a variety of drugs
- PDF / 169,659 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 107 Downloads / 206 Views
1
Osteonecrosis of the jaw associated with a variety of drugs A number of drugs appear to be associated with medication-related osteonecrosis of the jaw (MRONJ), according to finding of an analysis of case reports to the Australian Database of Adverse Event Notification (DAEN) published in the British Journal of Clinical Pharmacology. The Australian Therapeutic Goods Administration (TGA) provided a list of all case reports of MRONJ submitted to the DAEN between 1971 and October 2019. In total, 419 cases of MRONJ were reported between November 2015 and October 2018, and denosumab or bisphosphonates (alendronic, pamidronic, risedronic or zoledronic acid) were implicated in 405 cases. Denosumab was the only suspected agent in 221 cases, and was listed in addition to other possible causative agents in another 20 cases, while bisphosphonates were implicated in 163 reports . The most frequent possible secondary causative agents with antiresorptive properties included prednisolone (18 cases), cyclophosphamide (7), dexamethasone (5), lenalidomide (5) and thalidomide (5). Another 14 reports implicated secondary agents such as adalimumab and teriparatide. "This study presents several medications that may contribute to the pathogenesis of MRONJ, highlighting the importance of considering all possible medications that have effects on bone healing. Further research and improved MRONJ reporting are needed to verify the association of some of these drugs without anti-resorptive properties with MRONJ," concluded the authors. Teoh L, et al. Medication-related osteonecrosis of the jaw -analysing the range of implicated drugs from the Australian Database of Adverse Event Notifications. British 803521021 Journal of Clinical Pharmacology : 27 Nov 2020. Available from: URL: http://doi.org/10.1111/bcp.14681
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
